# Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT00097760** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 110 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Natalizumab
- **DRUG:** Natalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00097760
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2009-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097760, "Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00097760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*